Fortress Biotech CEO Explains The Company's Three-Step Business Model

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Companies within the fields of biotechnology and pharmaceuticals work to develop medicines for the treatment of various diseases and medical conditions. Typically, companies in both industries tend to focus their research on a specific branch of medicine (i.e., oncology, immunology, neurology, etc.).

And while most pharmaceutical and biotech companies focus solely on developing their own programs, Fortress Biotech FBIO takes a different approach to this classic business model. 

Fortress Biotech is a biopharmaceutical company that focuses on identifying promising drug candidates. Once identified, the company acquires, develops, and markets these assets with the help of its partner companies and collaborations with academic research institutions.

So, to better understand how this business model works, Chairman, President & CEO of Fortress Biotech Lindsay A. Rosenwald M.D., joined the recent Benzinga Global Small Cap Conference to further explain the company’s strategy.

The Ecosystem 

According to Dr. Rosenwald, globally, life science R&D spends as much as $400 billion annually, much of which focuses on the development of new medicines. He went on to explain that there are often opportunities to acquire these new research programs for a fraction of fair market value. Essentially, the company’s business model is to look for these opportunities.     

To provide a more comprehensive breakdown of this business model, the following outlines Fortress Biotech’s three-step process:

  • Step 1 – Fortress Biotech’s business development team identifies and evaluates the assets (clinical programs, drug candidates)
  • Step 2 – Fortress Biotech develops the assets with partner companies
  • Step 3 – Fortress Biotech and its partner companies find a way to generate income and monetize the assets as quickly as possible

“The whole idea is to use our business development team to find these development-stage programs that we think have a good chance of getting to the market in a reasonable period of time for a reasonable cost,” began Rosenwald. “Fortress Biotech then pairs these programs with our partner companies, keeps adding value to those partner companies by bringing more products to them, and helps them develop drug candidates.”

Product Pipeline

The business model Fortress Biotech created has led to the development of its diverse pipeline of products. Currently, the company, through its partner companies, has five marketed products, 26 product candidates, eight ongoing pre-clinical programs, and 27 ongoing clinical trials. 

Their pipeline also covers different branches of medicine. Given the company’s current portfolio, its main focus area is oncology/hematology, followed by rare/genetic diseases, dermatology, central nervous system disorders, infectious diseases, and pain.

Dr. Rosenwald explained that while other companies may focus on a specific disease or treatment modality, Fortress Biotech is not bound by either. Instead, they focus on opportunism and diversification.

“What differentiates Fortress Biotech from others in the industry is that most life science companies either focus on a therapeutic category like the central nervous system or cancer, or a treatment modality, whether it’s antibodies, cell therapy, small molecules or gene therapy,” said Rosenwald. “We care that the drug that we find looks like it works and that it is on a clear path to the market.”

Fortress Biotech has one New Drug Application (NDA) on file with the U.S. Food and Drug Administration (FDA) and anticipates another NDA filing with the FDA this year.
The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

Posted In: benzinga small cap conferenceFortress BiotechBiotechNewsPenny StocksSmall CapMarketsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.